On location in Orlando, Florida at the 2015 American Society of Hematology (ASH) annual meeting, MPN expert Dr. Claire Harrison, Hematologist at Guy and St. Thomas Hospital, covers the myeloproliferative neoplasm (MPN) highlights including drug and basic science research. Listen as she mentions key studies, both new for 2016 and ongoing with updated information. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Author: admin
At the 2015 National Cancer Research Institute (NCRI) Cancer Conference, Elaine Vickers, PhD, Founder and Principal Trainer of Science Communicated, Sheffield, UK, discusses her workshops that aim to explain the scientific concepts, including the molecular and cellular basis of cancer and their clinical application, behind the plenary lectures at the conference. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the role of neoadjuvant chemotherapy and the impact of the latest randomized trials in bladder cancer at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Immune checkpoint inhibitors in combination with chemotherapy or targeted agents for urothelial cancers at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Clinical trials in bladder cancer with Atezolizumab and Pembrolizumab at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses Adjuvant radiation v. chemo-RT v. chemotherapy alone after radical cystectomy for locally advanced bladder cancer at ASCO GU 2016
Matthew Galsky, MD Director of Genitourinary Medical Oncology at the Tisch Cancer Institute discusses the Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer at ASCO GU 2016
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, provides an overview if the Phase III clinical trial of ibrutinib vs chlorambucil in chronic lymphocytic leukemia (CLL) patients over the age of 65. Progression free survival (PFS) and overall survival (OS) were increased in the ibrutinib arm, demonstrating the superior efficacy of this drug over chlorambucil.
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the current treatment landscape in chronic lymphocytic leukemia (CLL), considering the novel therapies being presented at the American Society of Hematology (ASH) 2015 Annual Meeting.
Thomas J Kipps, MD from the University of California, San Diego, CA, discussed the impact of the clinical trial of venetoclax (ABT-199) with obinutuzumab in the treatment landscape chronic lymphocytic leukemia (CLL).
Thomas J Kipps, MD from the University of California, San Diego, CA, provides an overview of the clinical trial RESONATE-2 comparing ibrutinib with chlorambucil in chronic lymphocytic leukemia (CLL) patients not suitable to receive standard chemotehrapy. Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor, that targets B-cells and causes them to leave the lymph nodes and bone marrow. This drug has been shown to be effective in the treatment of CLL and therefore it has been approved in relapsed disease as a single-agent. Patients in the ibrutinib arm had a longer progression free survival (PFS), and survival advantage over chlorambucil.
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib. Prof. Dyer also discusses
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, discusses the importance of targeting proliferanting and quiescent chronic lymphocytic leukemia (CLL) cells. Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the use of ibrutinib as front-line therapy in chronic lymphocytic leukemia (CLL).
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the importance of Bcl-2-targeted therapies. They discuss recent sucesses of Bcl-2 targeting drugs, such as venetoclax (ABT-196) in the field of chronic lymphocytic leukemia.
At the American Society of Hematology (ASH) 2015 Annual Meeting, John Gribben, MD, DSc and Stephan Stilgenbauer, MD discuss the recent developments occuring in CLL and how certain molecules such as Bcl-2, BTK and PI3K, have moved from being biomarkers and stratification markers to becoming targets of the disease.
Barbara Eichhorst, MD from the Ludwig-Maximilians University, Munich, Germany, provides an overview of combination studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting held in Orlando, FL. Dr Eichhorst gives an overview of the Phase III clinical trial comparing chlorambucil with ibrutinib as front-line therapies, and an overview of the Phase II clinical trial of venetoclax in chronic lymphocytic leukaemia (CLL) patients with 17p deletion.
At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of new combination therapies involving hypomethylating agents. Dr Daver focuses on the following combinations: decitabine and vosarocin; decitabine and venetoclax (ABT-199); cytarabine and SGN-CD33A a CD33a monoclonal antibody .
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning for localized prostate cancer at ASCO 2016.
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses ongoing clinical trials that will establish a clinical role for molecular risk factors in prostate cancer at ASCO GU 2016.
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers that have been identified in prognosis and risk of relapse in localized prostate cancer at ASCO GU 2016
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers have greater impact on risk of recurrence than cancer stage and PSA levels at ASCO GU 2016
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses Genetic Testing in Prostate Cancer at ASCO GU 2016
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better results from ASCO GU 2016
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular targets in CRPC at ASCO GU 2016
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7 Splice Variant in prostate cancer at ASCO GU 2016 in San Francisco.
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses new recently discovered novel targets for CCRPC at ASCO GU 2016 in San Francisco.
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved agents such as abiraterone and enzalutamide at ASCO GU 2016 in San francisco.
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target molecular abnormalities in CRPC at ASCO GU 2016 in San Francisco.
Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the new data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on BGB-3111, a second generation Bruton’s tyrosine kinase (BTK) inhibitor. The data presented were obtained from a Phase I clinical trial, where the drug was well tolerated and demonstrated a good safety profile.
Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at the 2015 National Cancer Research Institute (NCRI) Cancer Conference. The session outlines current epidemiological and behavioural evidence on the relationship between different lifestyle choices and the development of cancer. The session hosted talks by Paolo Boffetta, Peter Anderson and Martin Wiseman, and focused on diet, exercise and alcohol consumption.
Alan Burnett, MD from Cardiff University, Cardiff, UK discusses the new technology developments in the field of acute myeloid leukemia (AML), at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL. He primarily discusses the use of genomic testing to provide a more accurate prognosis with conventional treatment, and the development of companion diagnostics (i.e. gene signatures that can help predict a response to a particular treatment). Other technologies discussed are the improvements on flow cytometry and its use in disease monitoring, in particular, we can now have a closer look at minimal residual disease. On the…
Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.
What is CLL? How and where does it start? CLL experts Dr. Nicole Lamanna of Columbia University Medical Center and Dr. Michael Keating of MD Anderson Cancer Center answer these questions, offering a clear and basic definition. Listen for Dr. Keating to share his insight about a possible future CLL vaccine. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
From our Ask the Expert series, CLL expert Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL question: Do inhibitor treatments have to be a lifelong medicine? Listen as Dr. Keating describes his personal disinclination for what he refers to as just controlling the disease and how he anticipates immunotherapy strategies being used to eventually eradicate CLL. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Dr. Michael Keating of MD Anderson Cancer Center answers the question: Does CLL return more aggressively after relapse than it was initially? Listen as Dr. Keating explores the tendencies of recurring CLL, including WBC doubling time and indolence. Get email alerts | http://www.patientpower.info/alerts Subscribe on YouTube | http://www.youtube.com/patientpower Like on Facebook | http://www.fb.com/patientpower.info Follow on Twitter | http://www.twitter.com/patientpower Follow on Google+ | http://www.google.com/+patientpowerinfo
Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco
Dr. Toni Choueiri, MD of Dana Farber gives an ASCO GU 2016 Update on Clear Cell and non-Clear Cell Renal Carcinomas from San Francisco.
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN Solid Tumor phase Ib trial at ASCO GU 2016.
Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic advanced setting to earlier disease states in urothelial cancers. ASCO GU 2016 in San Francisco
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial. at ASCO GU 2016 in San Francisco.
Dr. Nima Sharifi, MD of Cleveland Clinic comments on how investigators are now looking to use new therapies earlier within prostate cancer disease states which may be more effective from ASCO GU 2016.
Dr. Nima Sharifi, MD at Cleveland Clinic gives an overview of his presentation Androgen Receptor New Ways of Targeting the Old Target at ASCO Gu 2016 in San Francisco
Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in CRPC at ASCO GU 2016 in San francisco
Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in Castration Resistant Prostate Cancer at ASCO GU 2016 in San Francisco.
Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect current treatment paradigms for advanced prostate cancer at ASCO GU 2016 in San Francisco.
Nima Sharifi, MD of Cleveland Clinic discusses the new Androgen Receptor Signaling and the new targets and agents for advanced prostate cancer at ASCO GU 2016 in San Francisco.
Dr. Petros Grivas, MD at Cleveland Clinic discusses the correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features in urothelial carcinoma (UC) at ASCO GU 2016
Dr. Petros Grivas, MD at Cleveland Clinic discusses atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) at ASCO GU 2016 in San Francisco.